Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 13 Neoplasm Metastasis 10 Carcinoma, Medullary 10 Thyroid Neoplasms 5 Lung Neoplasms 5 Prostatic Neoplasms 3 Neoplasms 3 Adenocarcinoma 3 Familial medullary thyroid carcinoma 2 Colorectal Neoplasms 2 Carcinoma, Squamous Cell 2 Breast Neoplasms 2 Recurrence 1 Rectal Neoplasms 1 Pleural Effusion 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Multiple Myeloma 1 Mesothelioma 1 Head and Neck Neoplasms 1 Gallbladder Neoplasms 1 Differentiated Thyroid Cancer 1 Colonic Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Large Cell 1 Carcinoma, Hepatocellular 1 Carcinoma 1 Biliary Tract Neoplasms 1 Aggression 1 Advanced Breast Cancer 1

Interventions

vandetanib 1 midostaurin 1 glofitamab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Aggression × vandetanib × Clear all

NCT01945762 2024-12-18

Caprelsa104

Sanofi

Aggression, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡